AIM ImmunoTech Provides Update Regarding Annual Meeting
29 11월 2023 - 6:30AM
Business Wire
AIM Will Convene Annual Meeting on December 1st
and then Adjourn Until December 29th to Give Delaware Court
Additional Time to Deliver Ruling in Activist Group Litigation
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the
“Company”) today announced that the Company will convene its
upcoming 2023 Annual Meeting of Stockholders (the “2023 Annual
Meeting”) as planned on December 1, 2023, and will then adjourn
proceedings, without conducting any other business, until December
29, 2023. The purpose of the adjournment is to provide the Delaware
Court of Chancery (the “Court”) with sufficient time to issue a
ruling with respect to the litigation brought against the Company
and its directors by a member of a group of individuals who are
seeking to nominate three candidates for election to AIM’s
four-person Board of Directors (the “Board”) (collectively, the
“Activist Group”).
As a reminder, the AIM Board unanimously determined that the
Activist Group’s nomination notice (the “Notice”) is invalid
because it omits key information and includes misleading
information, ignoring what the Company’s Bylaws require to be
disclosed. Unless the litigation results in a finding that the
Notice is valid, the Company will not recognize the Activist
Group’s attempted nominations and any proxies submitted or votes
cast for the election of the individuals on the Activist Group’s
proxy card will be disregarded.
The record date for determining shareholders eligible to vote at
the 2023 Annual Meeting will remain the close of business on
October 2, 2023.
To learn more, visit: www.SafeguardAIM.com.
***
If you have any questions or require any
assistance in voting your shares, please contact our proxy
solicitor:
Morrow Sodali LLC 430 Park Avenue, 14th
Floor New York, NY 10022 Stockholders Call Toll Free: (800)
662-5200 Banks, Brokers, Trustees, and Other Nominees Call Collect:
(203) 658-9400 Email: AIM@investor.MorrowSodali.com
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the
research and development of therapeutics to treat multiple types of
cancers, immune disorders and viral diseases, including COVID-19.
The Company’s lead product is a first-in-class investigational drug
called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3
agonist immuno-modulator with broad spectrum activity in clinical
trials for globally important cancers, viral diseases and disorders
of the immune system.
For more information, please visit aimimmuno.com and connect
with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “continue,” “believe,” “potential,” “upcoming” and
other variations thereon and similar expressions (as well as other
words or expressions referencing future events or circumstances)
are intended to identify forward-looking statements. Many of these
forward-looking statements involve a number of risks and
uncertainties. The Company urges investors to consider specifically
the various risk factors identified in its most recent Form 10-K,
and any risk factors or cautionary statements included in any
subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities
and Exchange Commission (the “SEC”). You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Among other things, for
those statements, the Company claims the protection of safe harbor
for forward-looking statements contained in the PSLRA. The Company
does not undertake to update any of these forward-looking
statements to reflect events or circumstances that occur after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231128250087/en/
Investor Contact:
JTC Team, LLC Jenene Thomas 833-475-8247 AIM@jtcir.com
Media Contact:
Longacre Square Partners Joe Germani / Miller Winston
AIM@longacresquare.com
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024